Log in

Oncolytics Biotech Stock Forecast, Price & News

+0.03 (+0.87 %)
(As of 12/2/2020 12:00 AM ET)
Today's Range
Now: $3.49
50-Day Range
MA: $2.26
52-Week Range
Now: $3.49
Volume1.32 million shs
Average Volume873,241 shs
Market Capitalization$145.39 million
P/E RatioN/A
Dividend YieldN/A
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ONCY



Sales & Book Value

Annual SalesN/A


Net Income$-24,960,000.00


Market Cap$145.39 million
Next Earnings Date3/4/2021 (Estimated)
OptionableNot Optionable
+0.03 (+0.87 %)
(As of 12/2/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ONCY News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Oncolytics Biotech (NASDAQ:ONCY) Frequently Asked Questions

How has Oncolytics Biotech's stock been impacted by Coronavirus (COVID-19)?

Oncolytics Biotech's stock was trading at $1.74 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ONCY shares have increased by 100.6% and is now trading at $3.49.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Oncolytics Biotech?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Oncolytics Biotech
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Oncolytics Biotech?

Wall Street analysts have given Oncolytics Biotech a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oncolytics Biotech wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Oncolytics Biotech's next earnings date?

Oncolytics Biotech is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for Oncolytics Biotech

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech Inc. (NASDAQ:ONCY) posted its earnings results on Monday, November, 16th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.06.
View Oncolytics Biotech's earnings history

What price target have analysts set for ONCY?

4 Wall Street analysts have issued 12-month target prices for Oncolytics Biotech's stock. Their forecasts range from $6.00 to $9.00. On average, they anticipate Oncolytics Biotech's stock price to reach $7.33 in the next year. This suggests a possible upside of 110.1% from the stock's current price.
View analysts' price targets for Oncolytics Biotech

Are investors shorting Oncolytics Biotech?

Oncolytics Biotech saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,910,000 shares, an increase of 9.8% from the October 31st total of 1,740,000 shares. Based on an average trading volume of 570,700 shares, the days-to-cover ratio is currently 3.3 days. Currently, 4.5% of the shares of the stock are sold short.
View Oncolytics Biotech's Short Interest

Who are some of Oncolytics Biotech's key competitors?

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), KushCo (KSHB), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Cannabics Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

Who are Oncolytics Biotech's key executives?

Oncolytics Biotech's management team includes the following people:
  • Dr. Matthew C. Coffey, Pres, CEO & Director
  • Mr. Kirk J. Look C.A., CA, Chief Financial Officer
  • Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 53)
  • Mr. J. Mark Lievonen B.B.A., F.C.A., M.B.A., CM, FCPA, FCA, LLD, Consultant
  • Dr. Thomas C. Heineman M.D., Ph.D., Global Head of Clinical Devel. & Operations
  • Jon Patton, Director of Investor Relations & Communication
  • Dr. Grey Wilkinson Ph.D., Scientist of Translational Medicine
  • Dr. Daniel Douglas Von Hoff M.D., F.A.C.P., Consultant (Age 72)

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the NASDAQ under the ticker symbol "ONCY."

Who are Oncolytics Biotech's major shareholders?

Oncolytics Biotech's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.27%), International Assets Investment Management LLC (0.22%) and JPMorgan Chase & Co. (0.04%).

Which major investors are selling Oncolytics Biotech stock?

ONCY stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..

Which major investors are buying Oncolytics Biotech stock?

ONCY stock was bought by a variety of institutional investors in the last quarter, including International Assets Investment Management LLC, and JPMorgan Chase & Co..

How do I buy shares of Oncolytics Biotech?

Shares of ONCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oncolytics Biotech's stock price today?

One share of ONCY stock can currently be purchased for approximately $3.49.

How big of a company is Oncolytics Biotech?

Oncolytics Biotech has a market capitalization of $145.39 million. The company earns $-24,960,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

What is Oncolytics Biotech's official website?

The official website for Oncolytics Biotech is www.oncolyticsbiotech.com.

How can I contact Oncolytics Biotech?

Oncolytics Biotech's mailing address is 1167 Kensington Crescent Suite 210, Calgary A0, T2N 1X7. The company can be reached via phone at 403-670-7377 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.